Recent IPO activity remains steady into October 2026 despite elevated Treasury yields near 19-year highs and selective postponements. Multiple companies have priced offerings or filed S-1s in recent weeks, including SPACs and smaller issuers, while larger candidates such as Anthropic continue preparations for a potential late-2026 debut following confidential filings. Q3 saw notable volume led by SK hynix, though several AI-related deals faced delays tied to valuation concerns and volatility in the MOVE Index. With additional filings and scheduled listings through year-end, market-implied odds reflect broad trader consensus on continued IPO completions before 2027, supported by active pipelines in biotech, AI infrastructure, and blank-check vehicles. Key near-term catalysts include earnings releases and any Federal Reserve communications that could influence yield levels and risk appetite.